Allogene Stock Analysis

ALLO
 Stock
  

USD 10.82  0.15  1.41%   

The small slide in market price for the last few months could raise concerns from institutional investors as the firm is trading at a share price of 10.82 on 996,430 in volume. The company directors and management did not add much value to Allogene Therapeutics investors in September. However, diversifying your holdings with Allogene Therapeutics or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.8. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Allogene Therapeutics partners.
Please continue to Trending Equities.
  
The Allogene Therapeutics stock analysis report makes it easy to digest most publicly released information about Allogene Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Allogene Stock analysis module also helps to analyze the Allogene Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Allogene Stock Analysis Notes

About 30.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.34. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allogene Therapeutics recorded a loss per share of 2.08. The entity had not issued any dividends in recent years. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 334 people. For more info on Allogene Therapeutics please contact David Chang at 650 457 2700 or go to https://www.allogene.com.

Allogene Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Allogene Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Allogene Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Allogene Therapeutics generated a negative expected return over the last 90 days
Allogene Therapeutics has high historical volatility and very poor performance
Allogene Therapeutics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 205 K. Net Loss for the year was (303.84 M) with loss before overhead, payroll, taxes, and interest of (181.69 M).
Allogene Therapeutics currently holds about 449.05 M in cash with (203.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.13.
Roughly 65.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.benzinga.com: Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit - Allogen - Benzinga

Allogene Therapeutics Upcoming and Recent Events

Earnings reports are used by Allogene Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Allogene Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Allogene Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Allogene Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Allogene Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Allogene Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
9th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
20th of July 2022
Unclassified Corporate Event
View
12th of July 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event
View
21st of June 2022
Unclassified Corporate Event
View
17th of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders
View
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
14th of April 2022
Unclassified Corporate Event
View
7th of April 2022
Unclassified Corporate Event
View

Allogene Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Allogene Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Allogene Therapeutics backward and forwards among themselves. Allogene Therapeutics' institutional investor refers to the entity that pools money to purchase Allogene Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Tpg Gp A LlcCommon Shares18.7 M213.4 M
Vanguard Group IncCommon Shares8.4 M95.8 M
Blackrock IncCommon SharesM91.3 M
Woodline Partners LpCommon Shares5.9 M66.8 M
State Street CorpCommon Shares5.7 M64.5 M
Price T Rowe Associates IncCommon Shares5.6 M63.4 M
Primecap Management CoCommon Shares4.9 M55.7 M
Note, although Allogene Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Allogene Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.47 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Allogene Therapeutics's market, we take the total number of its shares issued and multiply it by Allogene Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (17.64) % which means that it has lost $17.64 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (31.57) %, meaning that it created substantial loss on money invested by shareholders. Allogene Therapeutics management efficiency ratios could be used to measure how well allogene therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 4th of October, Allogene Therapeutics shows the Risk Adjusted Performance of 0.0105, downside deviation of 5.16, and Mean Deviation of 3.89. Allogene Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Allogene Therapeutics, which can be compared to its rivals. Please confirm Allogene Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Allogene Therapeutics is priced correctly, providing market reflects its regular price of 10.82 per share. Given that Allogene Therapeutics has jensen alpha of 0.1213, we suggest you to validate Allogene Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Allogene Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triangular Moving Average shows Allogene Therapeutics double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
.

Allogene Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allogene Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allogene Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allogene Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Allogene Therapeutics Predictive Daily Indicators

Allogene Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Allogene Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Allogene Therapeutics Forecast Models

Allogene Therapeutics time-series forecasting models is one of many Allogene Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Allogene Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Allogene Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Allogene Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Allogene shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Allogene Therapeutics. By using and applying Allogene Stock analysis, traders can create a robust methodology for identifying Allogene entry and exit points for their positions.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 334 people.

Current Allogene Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Allogene analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Allogene analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
32.67Buy12Odds
Allogene Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Allogene analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Allogene stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Allogene Therapeutics, talking to its executives and customers, or listening to Allogene conference calls.
Allogene Analyst Advice Details

Allogene Stock Analysis Indicators

Allogene Therapeutics stock analysis indicators help investors evaluate how Allogene Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Allogene Therapeutics shares will generate the highest return on investment. By understating and applying Allogene Therapeutics stock analysis, traders can identify Allogene Therapeutics position entry and exit signals to maximize returns.
Quick Ratio12.48
Fifty Two Week Low6.43
Revenue Growth-99.80%
Shares Short Prior Month22.06M
Average Daily Volume Last 10 Day2.56M
Average Daily Volume In Three Month1.69M
Shares Percent Shares Out15.62%
Short Percent Of Float25.03%
Forward Price Earnings-3.60
Float Shares81.78M
Fifty Two Week High26.14
Enterprise Value To Ebitda-5.12
Fifty Day Average14.09
Two Hundred Day Average11.29
Enterprise Value To Revenue7,256.12
Please continue to Trending Equities. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for analysis

When running Allogene Therapeutics price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Allogene Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.